

QMS Nº: DIS/FMT/050

Rev. No: 0

Effective date: 18/06/2020 Ref. Doc.: LAW N° 003/2018

CLINICAL TRIAL APPROVAL

(Made under law No. 003/2018 of 09/02/2018 establishing the Rwanda FDA and determining its mission, organization and functioning in its article 8,paragraph 7 and article 9,paragraph 2)

Clinical Trial Approval No: 020/CTAC/FDA/2022

This is to certify that the clinical trial described below has been approved in Rwanda subject to conditions indicated in this certificate.

Protocol Title: "A Clinical Investigation Evaluating Efficacy of an Intelligent Cardiotocography with Real-Time Alerts for an Improved Labor and Delivery".

Protocol Number: SPIKER/RW/CT/CTG-AI | version 0.2

Name of the Investigational product (s):

Intervention (s)	Comparator (s)
• SPIKER AI-CTG(or EDAN CTG F9 powered by SPIKER AI)	• EDAN CTG F9

Clinical Trial site (s): La Croix du Sud Hospital, KIGALI.

Name of the Principal Investigator(s):
Dr. Kizito NKURIKIYEYEZU, PhD.

CRO/Research Institution (s): N/A Sponsor's name: Spiker Ltd, Japan.

Issued On: 11/10/2022 Expires on: 10/10/2023

Dr. Emile BIENVENO Director General

Key Conditions for compliance

- 1. To comply with eligibility criteria while recruiting participants as per trial protocol
- 2. To provide sufficient information to participant before recruitment for freely participation
- The Informed consent should always be obtained from the participant prior to enrollment
- 4. Changes, amendment, addendum to the study protocol or consent must be approved by Rwanda FDA prior to the implementation
- 5. Any Serious Adverse Events (SAEs) shall be notified to Rwanda FDA as soon as possible but not later than seven (7) calendar days using ADR/AEFI reporting form and submit complete report within eight (8) next calendar days.
- 6. Progress and final Report of the Clinical Trial shall be submitted to Rwanda FDA at prescribed Timelines

RWanda Food and Drugs Authority